BREAKING NEWS: New Hepatitis B Treatment Bepirovirsen Earns FDA Fast Track Status
GlaxoSmithKline's promising treatment for chronic hepatitis B, bepirovirsen, has been granted fast track status by the U.S. Food and Drug Administration (FDA), signaling a significant step forward in addressing this serious health condition.   Fast track designation is a recognition of the potential of bepirovirsen to address unmet medical needs in hepatitis B treatment. This status will...
0 Comments 0 Shares 9271 Views 0 Reviews